Drug Database
Back to search

Japan· JP-3999071F2028

ネランドミラスト

A nerandomilast product containing ネランドミラスト, registered in Japan by 日本ベーリンガーインゲルハイム, on the national reimbursement list. The same ATC class is registered in 9 of our 19 countries.

On Japan’s NHI price listATC L04AA61

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedネランドミラストATCL04AA61REGISTER NO.JP-3999071F2028PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ネランドミラストAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nerandomilast is registered in 9 of 19 countries.

Countries holding a registration under ATC L04AA61 (nerandomilast), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 5 of them publish a price we can compare per daily dose
Search nerandomilast products by name

Nerandomilast · ATC L04AA61

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
ネランドミラスト
Manufacturer
日本ベーリンガーインゲルハイム
Country
Japan (JP)
ATC code
L04AA61
ATC class
Nerandomilast
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same class

Other records under L04AA61

Nerandomilast, as other registers publish it.

All nerandomilast products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dd731904-e096-4c3f-9000-b3ff509a798d
GET /v1/drugs/dd731904-e096-4c3f-9000-b3ff509a798d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "１８ｍｇ１錠",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "3999071F2028",
  "category": "内用薬",
  "price_yen": 6561,
  "generic_name": "ネランドミラスト",
  "product_name_jp": null,
  "therapeutic_class": "3999",
  "transitional_expiry": "6561"
}
API referenceMCP serverPlans

See everything about nerandomilast.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console